NAGE
Niagen Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.50
+0.40%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.49
From 52W high−67.11%
Volume508774.00
Market cap$197.82M
P/E (TTM)12.9x
P/S (TTM)1.5x
Div yield—
Key dataOct 19, 2026
Open
$2.49
From 52W high
−67.11%
Volume
508774.00
Market cap
$197.82M
ValuationView details →
P/E (Fwd)
27.0x
EV/EBITDA
7.3x
P/E (TTM)
12.9x
RSI (14)
30.6
MomentumView details →
1D Return
+0.40%
YTD Return
−60.61%
SummaryUpdated Jun 1, 2026
ChromaDex Corporation (NASDAQ:CDXC) is a bioscience company founded in 1999 and headquartered in Los Angeles, California. The company specializes in healthy aging research and is a leader in the development of nicotinamide adenine dinucleotide (NAD) precursor technologies. ChromaDex went public in 2015 and has evolved from a contract research organization into a consumer health company focused on NAD boosting supplements and potential pharmaceutical applications. The company is known for its proprietary ingredient Niagen and its consumer brand TRU NIAGEN, which targets the growing market of consumers interested in longevity and cellular health optimization.
Similar companies
Latest newsMore news →
Niagen Bioscience announced that it will release its third-quarter 2026 financial results after market close on November 4, 2026, and hold a conference call at 4:30 p.m. ET that day.5d agoNiagen Bioscience's wholly owned subsidiary NAD Pharmaceuticals Corp. engaged life sciences advisory firm Red Sky Partners to support advancement of its investigational drug candidate NB4168.33d ago